drugset

drugset / Trial / NCT07269717

A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction

NCT07269717 ↗

Phase 2 Recruiting 48 enrolled Shandong Suncadia Medicine Co., Ltd.

RandomizedParallel-groupTriple-blindTreatment

Summary

This study aims to evaluate the safety and tolerability of HRS-1893 in subjects with heart failure with preserved ejection fraction.

Timeline

Start: 2026-03-30
Primary completion: 2027-03
Completion: 2027-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HRS-1893	Unknown	—	—

Indications